With more than 30 clinical trials currently underway for the treatment of inherited retinal diseases (IRDs), it’s imperative that clinicians are aware of the most recent information to get patients on the appropriate paths to clinical trials and future therapies.
Age-related macular degeneration (AMD) is the leading cause of legal blindness in adults over age 50. The development of agents that target vascular endothelial growth factor (VEGF) has revolutionized the treatment of AMD. However, optimal AMD management is impeded by challenges in access to FDA-approved therapies.
Here you will find education on IRDs and AMD that provides insights, guidelines, and information to help you optimize the management of your patients.
Live Webcast: Inherited Retinal Diseases Overview, Patient Resources, and Clinical Trials
 [themo_button text=”Register Now” url=”https://www.cmeoutfitters.com/transfers/cm/?ID=37654″ type=”standard” target=”_blank”] |
Monday, May 18, 2020 | 12:00pm – 1:00pm ET
In this live webcast brought to you by the Foundation Fighting Blindness and CME Outfitters, Dr. Jacque Duncan will share expert insights and tips to prepare you to confidently summarize IRDs and their impact on patients; identify benefits of IRD genetic testing, genetic counseling, and patient registries; and review current clinical trials for emerging therapies for IRD. |
Keeping the Patient in the Center in AMD Care
 [themo_button text=”Participate Now” url=”https://www.cmeoutfitters.com/hub-activity/keeping-the-patient-in-the-center-in-amd-care/” type=”standard” target=”_blank”] |
The first part of this CME Outfitters Snack series on overcoming the challenges of prior authorization when treating patients with AMD features expert faculty discussing how to implement patient-centric care models that incorporate shared decision-making, which is imperative to educating patients on the benefits and risks of FDA-approved and off-label agents for the treatment of AMD. |
Minimizing the Burden of Prior Authorization in AMD Through Actionable Strategies and Improved Communication
 [themo_button text=”Participate Now” url=”https://www.cmeoutfitters.com/hub-activity/minimizing-the-burden-of-prior-authorization-in-amd-through-actionable-strategies-and-improved-communication/” type=”standard” target=”_blank”] |
In order to decrease the burden of prior authorization for AMD treatments, the second module of this CME Outfitters Snack series aims to provide learners with strategies to improve documentation and establish clear communication with the payer to minimize treatment delays. |
Honing in on the Appeal Process to Improve Access to Anti-VEGF Therapy for Patients with AMD
 [themo_button text=”Participate Now” url=”https://www.cmeoutfitters.com/transfers/cm/?ID=32563″ type=”standard” target=”_blank”] |
Step therapy requirements have limited patient access to FDA-approved, anti-VEGF agents for the treatment of AMD. Prior authorization requests for these therapies are commonly denied. Hence, it is important that clinicians be aware of the approaches to overcome these barriers and implement systemic and clinically supported appeals that ensure uninterrupted anti-VEGF therapy for patients with AMD. In the third module of this CME Outfitters Snack series, expert faculty focus on developing and implementing strategies for appeals in order to reduce treatment delays. |
Zooming in on the Education and Empowerment of Patients in AMD Care
 [themo_button text=”Participate Now” url=”https://www.cmeoutfitters.com/hub-activity/zooming-in-on-the-education-and-empowerment-of-patients-in-amd-care/” type=”standard” target=”_blank”] |
The final module of this CME Outfitters Snack series describes step therapy policies and their implications for the patient, with the goal of educating clinicians on the increased risk of these policies, including the possibility of increased medical costs and worsening of the disease, so that they can pass this knowledge on to their patients with AMD and work together to navigate through the PA process. |